Medicine Nobel splits 12 million kronor three ways for the algal light switch

The Nobel Assembly at Karolinska Institutet awarded the 2026 prize in physiology or medicine on Monday to Karl Deisseroth, Peter Hegemann and Georg Nagel for the work that turned a protein from a pond alga into a light switch for nerve cells. The prize is 12 million Swedish kronor, to be shared equally. The citation is "for their discoveries concerning light-gated ion channels and optogenetics."

Hegemann is at Humboldt University of Berlin. Nagel is at the University of Wurzburg. Deisseroth is at Stanford University and the Howard Hughes Medical Institute. The Assembly's account splits the labour cleanly. Hegemann and Nagel found channelrhodopsin in a single-celled alga. Deisseroth turned that protein into a way to control nerve cells with light. The plain-language heading on the release is that light-seeking algae gave neuroscience a switch.

The method is optogenetics. A nerve cell that has been given the algal protein will open an ion channel when a specific light hits it. Opening the channel can make the cell fire, or, with later variants, keep it from firing. A researcher can then ask what a memory, a movement or a feeling does when one identified group of cells is switched on or off in a living brain. That is the claim the Assembly made: the discoveries make it possible to show how nerve cells shape memories, feelings and behaviours in the living brain.

The alga is the part that is easy to miss in a prize framed as brain science. Channelrhodopsin is a microbial protein. It evolved to steer a cell toward or away from light, not to explain the hippocampus. Hegemann and Nagel's work was on that protein. Deisseroth's move was to put it into neurons and use light as the control. The prize is for both steps. A committee that honoured only the brain application would have misstated where the tool came from.

The money split is equal, which is a choice. Three laureates and one sum of 12 million kronor means 4 million each, before tax and before the share institutions sometimes claim. Physics, announced the next day, gave the whole 12 million to Francis Halzen. Medicine split its sum three ways. The two announcements, on 5 and 6 October, are the first half of Nobel week. The practical difference for laboratories is not the cheque. It is that optogenetics is now a Nobel method, which changes how grant panels treat a technique many of them already use.

Deisseroth's Stanford and HHMI base, Hegemann's Berlin base and Nagel's Wurzburg base also mark the geography of the tool. The protein work was German. The conversion into a standard neuroscience method was American, in a lab that spent years showing other groups how to use it. Labs that now order the viral vectors and the light hardware are downstream of both. The Assembly's secretary-general is Thomas Perlmann. The press contact on the release is Pernilla Witte.

What the prize does not do is turn optogenetics into a treatment. The citation is about discoveries and a method for studying the living brain. Clinical uses of light-gated channels remain a separate, slower track. A reader who leaves with one fact should leave with the division of labour: two Germans found the algal switch, an American put it into neurons, and the Assembly paid all three the same share on 5 October.

Channelrhodopsin's practical property is speed. Chemical drugs wash in and out over minutes. A light pulse can open the algal channel in milliseconds, which is the timescale of a nerve impulse. That is why the method could move from a pond organism to a question about memory. The Assembly's release does not set out the wavelength or the viral-delivery steps. Those are in the papers. The prize text stops at the discovery and the use.